Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health (CVD) reported encouraging results from an early clinical trial that tested a new dual vaccine against Lassa fever and rabies. The study, published today in the journal Nature Medicine, found that the vaccine was safe and induced immune responses against both viruses. There are currently no vaccines against Lassa fever on the market.